Bod Australia (ASX:BOD) - CEO, Jo Patterson
CEO, Jo Patterson
Source: Wise Owl
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bod Australia (BOD) sees positive results from its study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract
  • The study is part of the basis for the launch of a new medical cannabis product that will be sold under the company’s existing medicinal cannabis brand, MediCabilis CBG 50
  • The new product is expected to launch next month
  • CBG has shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others
  • BOD shares are in the grey and trading at 14 cents per share at 1:00 pm AEST

Bod Australia (BOD) has seen positive results from its study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract.

The study is part of the basis for the launch of a new medical cannabis product that will be sold under the company’s existing medicinal cannabis brand, MediCabilis CBG 50. The new product is expected to launch next month.

CBG is a non-intoxicating cannabinoid compound found in the cannabis plant. The extract has shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others.

The study was completed over three months to assess the safety and efficacy of the drug in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety.

In the trial, 74 per cent of participants noticed improvements to their condition within two to four weeks of using MediCabilis CBG 50.

Trial data will be shared with doctors and approved prescribers in both Australia and the UK to help in the ongoing educational initiative undertaken by the company.

“The completion of this initiative has highlighted that MediCabilis CBG 50 is both safe
and effective for use across a range of new symptoms that our product has not been previously prescribed for,” CEO Jo Patterson said.

“The study will also allow Bod to explore the possibility of using its extract as an alternative treatment or all encompassing route for conditions that require a mix of surgery, medication and other routines.”

On the market this afternoon, BOD shares were in the grey and trading at 14 cents per share at 1:00 pm AEST.

BOD by the numbers
More From The Market Herald

" Empire Resources (ASX:ERL) records further multi-element mineralisation at Yuinmery, WA

Empire Resources (ASX:ERL) has intersected more multi-element mineralisation at its Yuinmery project in Western Australia.

" R3D Resources (ASX:R3D) to commence drilling in QLD this weekend

R3D Resources (ASX:R3D) is gearing up to commence a drilling program at key copper and zinc…
The Market Herald Video

" DDH1 (ASX:DDH) launches share-buy back

DDH1 (ASX:DDH) has launched an on-market share buy-back program of up to 10 per cent of…
The Market Herald Video

" Lithium Australia’s (ASX:LIT) Envirostream receives first cash rebate for B-cycle scheme

Lithium Australia's (ASX:LIT) subsidiary, Envirostream Australia has received its first cash rebate for the B-cycle scheme.